Published in
Oxford University Press, Clinical Infectious Diseases, 10(52), p. 1212-1217, 2011
DOI: 10.1093/cid/cir183
Links
- ORCID
- Oxford University Press
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Randomized, Placebo-Controlled Phase 2 Trial of a Lactobacillus crispatus Probiotic Given Intravaginally for Prevention of Recurrent Urinary Tract Infection
Journal article published in 2011 by
Ann E. Stapleton 
,
Melissa Au-Yeung,
Thomas M. Hooton,
David N. Fredricks,
Pacita L. Roberts,
Christopher A. Czaja,
Yuliya Yarova-Yarovaya,
Tina Fiedler,
Marsha Cox,
Walter E. Stamm
,
Melissa Au-Yeung,
Thomas M. Hooton,
David N. Fredricks,
Pacita L. Roberts,
Christopher A. Czaja,
Yuliya Yarova-Yarovaya,
Tina Fiedler,
Marsha Cox,
Walter E. Stamm
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
In a double-blind placebo-controlled trial of a Lactobacillus crispatus intravaginal suppository probiotic (LACTIN-VÜ, Osel, Inc.) for prevention of recurrent UTI (rUTI) in pre-menopausal women, LACTIN-V was safe, well tolerated, and associated with a reduction in rUTI.